Gly388Arg FGFR4 Polymorphysm is Not Predictive of Everolimus Efficacy in Gastrointestinal Well Differentiated Neuroendocrine Tumors (NET)

#1119

Introduction: Preclinical data suggest that single nucleotide polymorphism substituting an arginine (R) for glycine (G) in codon 388 of the FGFR4 transmembrane domain may increase proliferation of xenografted neuroendocrine cell lines and decrease their sensitivity to everolimus by modulating STAT3 signaling and the mTOR pathway.

Aim(s): To evaluate the prognostic and predictive values of this polymorphism on everolimus efficacy in patients treated for a digestive NET.

Materials and methods: This monocentric retrospective cohort included patients with small bowel NET (SBNET) and pancreatic NET (PNET) treated by everolimus (2006-2013). Patients were genotyped by classical sequencing and mTOR pathway activity assessed by immunochemistry on FFPE samples (PTEN/pPTEN/pAKT/pmTOR/pS6/p4EBP1).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Cros J

Authors: Cros J, Moati E, Raffenne J, Hentic O, Svrcek M,

Keywords: N,